{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:54:45Z","timestamp":1792652085552,"version":"4.5.0"},"reference-count":75,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2024,12,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infections and hospitalization in infants and the elderly. Newly approved vaccines and the prophylactic antibody nirsevimab have heightened interest in RSV immunologic surveillance, necessitating the development of high-throughput assays assessing anti-RSV neutralizing activity. Quantitative viral neutralization remains the best correlate of protection for RSV infection and the gold standard for RSV immunological testing. Here, we developed a high-throughput RSV strain A2 focus-reduction neutralization test validated to Clinical Laboratory Improvement Amendments (CLIA)\/ Good Clinical Laboratory Practices (GCLP) standards using both clinical specimens and commercially available reference sera. The assay is highly accurate, generating reference serum neutralizing titers within twofold of established assays, with an analytical measurement range between 8 and 1,798 international units per mL (IU\/mL). Neutralizing activity measured by the assay strongly correlated with antibody titer determined via indirect enzyme-linked immunosorbent assay (ELISA) (\n              <jats:italic>\u03c1<\/jats:italic>\n              = 1.0,\n              <jats:italic>P<\/jats:italic>\n              = 0.0014). Individuals recently having tested positive via quantitative reverse transcription polymerase chain reaction (RT-qPCR) for RSV had a 9.1-fold higher geometric mean neutralizing titer relative to RSV PCR negatives (\n              <jats:italic>P<\/jats:italic>\n              -value = 0.09). The validated assay was then used to investigate the immunity debt hypothesis for resurgent RSV outbreaks in the 2022\u20132023 season, using adult clinical remnant sera sent for herpes simplex virus (HSV)-1\/2 antibody testing. There was no difference in geometric mean anti-RSV neutralizing titers between sera sampled before and after the 2022\u20132023 RSV outbreak (\n              <jats:italic>P<\/jats:italic>\n              = 0.68). These data are consistent with limited changes in RSV-neutralizing antibody levels in adults across the 2022\u201323 RSV outbreak.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>IMPORTANCE<\/jats:title>\n            <jats:p>Population surveillance studies of serum-neutralizing activity against RSV are crucial for evaluating RSV vaccine efficacy and vulnerabilities to new strains. Here, we designed and validated a high-throughput assay for assessing anti-RSV neutralizing activity, standardized its measurements for comparison with other methodologies, and demonstrated its applicability to real-world samples. Our assay is precise, linear, and yields measurements consistent with other standardized assays, offering a methodology useful for large-scale studies of RSV immunity. We also find no significant difference in neutralizing titers among adults between those taken before and after large RSV outbreaks associated with the latter stages of the coronavirus disease of 2019 (COVID-19) public health emergency, underlining the need for a greater understanding of the dynamics of serological responses to RSV infection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/spectrum.02115-24","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T13:02:14Z","timestamp":1730206934000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["Clinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021\u20132023 RSV outbreaks to investigate the immunity debt hypothesis"],"prefix":"10.1128","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9278-3907","authenticated-orcid":false,"given":"Eli A.","family":"Piliper","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington Medical Center","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington Medical Center","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-0527","authenticated-orcid":true,"given":"Alexander L.","family":"Greninger","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington Medical Center","place":["Seattle, USA"]},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"Respiratory Syncytial Virus (RSV) | NIH: National Institute of Allergy and Infectious Diseases. 2022. Available from: https:\/\/www.niaid.nih.gov\/diseases-conditions\/respiratory-syncytial-virus-rsv. Retrieved 10 Jun 2023."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.11.106"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2022.12.010"},{"key":"e_1_3_3_5_2","unstructured":"Commissioner O of the. 2023. FDA approves first respiratory syncytial virus (RSV) vaccine. FDA. FDA. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913556"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/v15020280"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00544-8"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/idr14040059"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S396434"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14647"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00749-3"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00085-21"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01113-x"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae140"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1115353"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2021.10.001"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac192"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/v15040939"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02316-5"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2017.0147"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(81)80829-3"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-64-9-1867"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(06)80027-2"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.10.043"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.07.053"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2009.09.006"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.10.046"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/1348-0421.12201"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2018.10.022"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.04.053"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00225-17"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S438915"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav9033"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.095"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.10.087"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa0698"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.9.6.1235-1239.2002"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2021.113160"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250516"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06179-11"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00003-08"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03789-22"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2022.114590"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2021.113054"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.06.017"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11071789"},{"key":"e_1_3_3_48_2","unstructured":"Santana-Rodr\u00edguez E M\u00e9ndez-Orta MK Sardina-Gonz\u00e1lez T Pilar M Brizuela SC Sordo-Puga Y P\u00e9rez-P\u00e9rez D Oliva-C\u00e1rdenas A Vargas-Hern\u00e1ndez M Duarte CA Fr\u00edas-Lepoureaux MT Su\u00e1rez-Pedroso M. 2022. Consistency of the neutralizing peroxidase linked assay for classical swine fever and homologation with an OIE reference laboratory"},{"key":"e_1_3_3_49_2","first-page":"2496","article-title":"Establishment and validation of competitive ELISA for detecting blocking activity of monoclonal antibody against SARS-CoV-2 RBD","author":"Pan YB","year":"2020","unstructured":"Pan YB, Zhang N, Zhan SS, Gui F, Wang J, Song G, Wu XL, Yang XM. 2020. Establishment and validation of competitive ELISA for detecting blocking activity of monoclonal antibody against SARS-CoV-2 RBD. Chin J New Drugs:2496\u20132501.","journal-title":"Chin J New Drugs"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262922"},{"key":"e_1_3_3_51_2","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster DA","year":"2008","unstructured":"Armbruster DA, Pry T. 2008. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev Aust Assoc Clin Biochem 29:S49\u201352.","journal-title":"Clin Biochem Rev Aust Assoc Clin Biochem"},{"key":"e_1_3_3_52_2","unstructured":"2024. RSV State Trends - NREVSS | CDC. Available from: https:\/\/www.cdc.gov\/surveillance\/nrevss\/rsv\/state.html"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207566"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2022.123409"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3687-8_7"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213836"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.03.017"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.15108.1"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175792"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081717"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-38919-1_3"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad076"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2284"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.06.016"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab612"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00763-0"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","unstructured":"Walker G Foster C Sevendal A Domazetovska A Kamalakkannan A Williams PCM Kim KW Condylios A Stelzer-Braid S Bartlett A Rawlinson W. 2023. Genomic and immunological characterisation shows increased respiratory syncytial virus cases not due to waning antibody mediated immunity. SSRN. Rochester NY. doi:10.2139\/ssrn.4515871","DOI":"10.2139\/ssrn.4515871"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102089"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26370"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060624"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28830"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2904.221834"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2216153"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(96)00096-5"},{"key":"e_1_3_3_75_2","unstructured":"Landis JT Peng A An H Bailey AG Dittmer DP Marron JS. 2021 dr4pl: dose response data analysis using the 4 parameter logistic (4pl) Model (2.0.0)"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj0902029"}],"updated-by":[{"DOI":"10.1128\/spectrum.00412-25","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000}}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02115-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02115-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:09:51Z","timestamp":1733407791000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.02115-24"}},"subtitle":[],"editor":[{"given":"Meghan","family":"Starolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,5]]}},"alternative-id":["10.1128\/spectrum.02115-24"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.02115-24","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"2024-08-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02115-24"}}